Further, we have continuously identified that disrupting CaV2.2–CRMP2 binding with tat-CBD3, myr-tat-CBD3 peptides, or CBD3063 does not affect memory, locomotion, nor anxiety/depression, and does not produce addictive behaviors7,23,24. The gene discussed is DPYSL2; the disease is depressive symptom measurement.